Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::NTRK1 status confers therapeutic sensitivity to Repotrectinib in patients with Any solid tumor.
This statement is based on a regulatory approval from the European Medicines Agency:
AUGTYRO as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with advanced solid tumors expression NTRK gene fusions, and (i) who have received a prior NTRK inhibitor, or (ii) have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinial benefit, or have been exhausted.